Literature DB >> 17129764

What is immune privilege (not)?

Ian Galea1, Ingo Bechmann, V Hugh Perry.   

Abstract

The 'immune privilege' of the central nervous system (CNS) is indispensable for damage limitation during inflammation in a sensitive organ with poor regenerative capacity. It is a longstanding notion which, over time, has acquired several misconceptions and a lack of precision in its definition. In this article, we address these issues and re-define CNS immune privilege in the light of recent data. We show how it is far from absolute, and how it varies with age and brain region. Immune privilege in the CNS is often mis-attributed wholly to the blood-brain barrier. We discuss the pivotal role of the specialization of the afferent arm of adaptive immunity in the brain, which results in a lack of cell-mediated antigen drainage to the cervical lymph nodes although soluble drainage to these nodes is well described. It is now increasingly recognized how immune privilege is maintained actively as a result of the immunoregulatory characteristics of the CNS-resident cells and their microenvironment.

Entities:  

Mesh:

Year:  2006        PMID: 17129764     DOI: 10.1016/j.it.2006.11.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  277 in total

Review 1.  The immunology of acute stroke.

Authors:  Ángel Chamorro; Andreas Meisel; Anna M Planas; Xabier Urra; Diederik van de Beek; Roland Veltkamp
Journal:  Nat Rev Neurol       Date:  2012-06-05       Impact factor: 42.937

Review 2.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

4.  Neuron-Microglia Dialogue and Hippocampal Neurogenesis in the Aged Brain.

Authors:  Carmelina Gemma; Adam D Bachstetter; Paula C Bickford
Journal:  Aging Dis       Date:  2010-12-01       Impact factor: 6.745

5.  Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.

Authors:  Daniel Larocque; Nicholas S R Sanderson; Josée Bergeron; James F Curtin; Joe Girton; Mia Wibowo; Niyati Bondale; Kurt M Kroeger; Jieping Yang; Liliana M Lacayo; Kevin C Reyes; Catherine Farrokhi; Robert N Pechnick; Maria G Castro; Pedro R Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

Review 6.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

Review 7.  The myeloid cells of the central nervous system parenchyma.

Authors:  Richard M Ransohoff; Astrid E Cardona
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 8.  Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.

Authors:  Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2017-07-15       Impact factor: 3.969

9.  Conditional Silencing of H-2Db Class I Molecule Expression Modulates the Protective and Pathogenic Kinetics of Virus-Antigen-Specific CD8 T Cell Responses during Theiler's Virus Infection.

Authors:  Zachariah P Tritz; Robin C Orozco; Courtney S Malo; Katayoun Ayasoufi; Cori E Fain; Roman H Khadka; Emma N Goddery; Lila T Yokanovich; Megan L Settell; Michael J Hansen; Fang Jin; Kevin D Pavelko; Larry R Pease; Aaron J Johnson
Journal:  J Immunol       Date:  2020-07-31       Impact factor: 5.422

10.  Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.

Authors:  Haitao Fan; Ian Zhang; Xuebo Chen; Leying Zhang; Huaqing Wang; Anna Da Fonseca; Edwin R Manuel; Don J Diamond; Andrew Raubitschek; Behnam Badie
Journal:  Clin Cancer Res       Date:  2012-08-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.